Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin 15 - Admune Therapeutics

Next Previous
Search
Drug Profile

Interleukin 15 - Admune Therapeutics

Alternative Names: Heterodimeric IL-15; Heterodimeric Interleukin 15; hetIL-15; IL 15; NIZ985; sIL 15Ra

Latest Information Update: 25 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Admune Therapeutics
  • Developer Admune Therapeutics; National Cancer Institute (USA); Novartis
  • Class Adjuvants; Immunotherapies; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Dec 2023 Novartis Pharmaceuticals terminates the phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Germany, Italy, Japan, Spain, Taiwan and USA due to business decision (NCT04261439)
  • 03 Nov 2023 Interleukin 15 is still in phase I trials for Solid tumours in Japan and USA
  • 20 Oct 2023 Updated adverse events and pharmacokinetics data from a phase I/Ib trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top